Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC and Bristol-Myers Squibb XIGDUO receives approval in european union for type 2 diabetes

Wednesday, 22 Jan 2014 02:00am EST 

AstraZeneca PLC and Bristol-Myers Squibb:Says Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union (EU).Says Xigduo combines dapagliflozin (trade name Forxiga), a selective and reversible inhibitor of SGLT2 with metformin hydrochloride, two anti-hyperglycaemic products with complementary mechanisms of action to improve glycaemic control, in a twice daily tablet.Says this is the first regulatory approval for a fixed dose combination of an SGLT2 inhibitor and metformin. 

Company Quote

2 Jun 2015